Breakpoint Therapeutics aims to advance the clinical improvement of initial-in-class oncology medicines that interfere with DNA mend and replication pressure tolerance pathways. The business’s therapeutics focus on the DNA injury response in cancer cells with repair service and replication pressure tolerance pathways, enabling the health care organisation and hospitals to https://is.gd/VVmTMJ